The US FDA has expanded the approval of evinacumab-dgnb (Evkeeza) to include patients aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). The drug, which inhibits lipoprotein lipase and endothelial lipase, showed a significant reduction in LDL-cholesterol levels in a study of 20 patients in this age group. Safety and efficacy data were similar to those in older patients with HoFH.
Naar een andere taal
vanuit de broninhoud
www.medscape.com
Belangrijkste Inzichten Gedestilleerd Uit
by Steve Stiles om www.medscape.com 03-22-2023
https://www.medscape.com/viewarticle/990016Diepere vragen